Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Simulations Plus, Inc. (SLP)
Last simulations plus, inc. earnings: 4/9 04:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
simulations-plus.com/software/overview
Company Research
Source: Business Wire
SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. Food and Drug Administration (FDA) in 2024.“For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of healthcare,” said Shawn O’Connor, Chief Executive Officer at Simulations Plus. “We are proud that our advanced modeling and simulation software and consulting services supported the development of every drug approved by the FDA in 2024. This achievement u
Show less
Read more
Impact Snapshot
Event Time:
SLP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLP alerts
High impacting Simulations Plus, Inc. news events
Weekly update
A roundup of the hottest topics
SLP
News
- Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development [Yahoo! Finance]Yahoo! Finance
- Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug DevelopmentBusiness Wire
- Simulations Plus (NASDAQ:SLP) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date [Yahoo! Finance]Yahoo! Finance
SLP
Earnings
- 12/1/25 - In-Line
SLP
Sec Filings
- 12/8/25 - Form 8-K
- 12/2/25 - Form 4
- 12/1/25 - Form 144
- SLP's page on the SEC website